Frequently asked questions
The global Calprotectin testing market was valued at USD 195.8 Billion in 2022.
The Calprotectin testing market is expected to grow at a CAGR of 5.80% between 2023 and 2030, reaching USD 290.5 Billion in 2030.
The Stool segment is the main segment due of its excellent accuracy and non-invasive character.
The Diagnostic Laboratories category is predicted to be the second-largest market for Calprotectin testing.
In the Calprotectin testing market, the Ulcerative Colitis category is predicted to develop at the fastest CAGR.
North America is projected to lead the Calprotectin testing market.
The top players include Actim Oy, Calpro AS, BUHLMANN Laboratories AG, EagleBio and Cer Test Biotec S.L. Other major players include Biohit Oyj, American Laboratory Products Company, Ltd, DIAsource ImmunoAssays S.A and R-Biopharm AG.
Inflammatory Bowel Disease (IBD) is growing increasingly widespread, and the need of early detection and treatment is becoming more widely recognized are the major market drivers.
Online Calprotectin testing is still standardized, and policies of limited reimbursement are in place are the major market restraints.
Non-Invasive Diagnostic Tools are in great demand, and the emphasis on non-invasive testing is increasing are the major opportunities in the Calprotectin testing industry.